Follow The Filings

MAZE Maze Therapeutics Inc.

Health Care, filed as MAZE THERAPEUTICS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 0.4%
  • $32M

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Nathan Fischel, DAFNA Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.38%
  2. Farallon Capital Management 0.13%

Who owns MAZE

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 0.13% Hold 1,107,814 $30M History
Nathan Fischel, DAFNA Capital Management 0.38% Hold 65,000 $1.8M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MAZE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MAZE insider trades
  • None no insider bought on the open market
  • $1.1M sold by 1 insider outside a trading plan
  • $22.7M sold by 4 insiders under 10b5-1 plans
  1. Jason V. Coloma CEO
    Planned sale
    $1M 34,501 shares at $30.25 16% of stake
    Traded Nov 2 Filed Nov 4
  2. Atul Dandekar Csbo
    Planned sale
    $241K 7,500 shares at $32.07 19% of stake
    Traded Oct 29 Filed Oct 30
  3. Harold Bernstein President, R&D & CMO
    Planned sale
    $435K 16,141 shares at $26.93 100% of stake
    Traded Oct 1 Filed Oct 2
  4. Jason V. Coloma CEO
    Planned sale
    $932K 34,501 shares at $27.02 15% of stake
    Traded Oct 1 Filed Oct 2
  5. Atul Dandekar Csbo
    Planned sale
    $203K 7,500 shares at $27.06 19% of stake
    Traded Sep 29 Filed Oct 1
  6. Harold Bernstein President, R&D & CMO
    Planned sale
    $255K 9,705 shares at $26.22 100% of stake
    Traded Sep 4 Filed Sep 8
  7. Harold Bernstein President, R&D & CMO
    Planned sale
    $426K 16,141 shares at $26.36 100% of stake
    Traded Sep 1 Filed Sep 3
  8. Jason V. Coloma CEO
    Planned sale
    $907K 34,501 shares at $26.29 13% of stake
    Traded Sep 1 Filed Sep 3
  9. Atul Dandekar Csbo
    Planned sale
    $207K 7,500 shares at $27.58 22% of stake
    Traded Aug 28 Filed Aug 31
  10. Harold Bernstein President, R&D & CMO
    Planned sale
    $446K 16,142 shares at $27.61 100% of stake
    Traded Aug 13 Filed Aug 14
  11. Jason V. Coloma CEO
    Planned sale
    $922K 34,501 shares at $26.73 12% of stake
    Traded Aug 3 Filed Aug 5
  12. Atul Dandekar Csbo
    Planned sale
    $205K 7,500 shares at $27.34 22% of stake
    Traded Jul 29 Filed Jul 31
  13. Harold Bernstein President, R&D & CMO
    Planned sale
    $437K 14,609 shares at $29.90 100% of stake
    Traded Jul 1 Filed Jul 2
  14. Jason V. Coloma CEO
    Planned sale
    $1M 34,501 shares at $29.98 11% of stake
    Traded Jul 1 Filed Jul 2
  15. Atul Dandekar Csbo
    Planned sale
    $210K 7,500 shares at $28.02 22% of stake
    Traded Jun 29 Filed Jul 1

Also filed in the last 12 months, not counted as buying or selling: 49 option exercises, 16 sales to cover taxes, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 1.01,3.02,9.01
8-K 5.02,7.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
8-K 5.07

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2025
Net income -$131.12M

Balance sheet

Metric FY2025
Total current assets $349.72M
Total non-current assets * $47.41M
Total assets $397.13M
Total current liabilities $22.56M
Total non-current liabilities * $19.6M
Total equity $354.97M

Cash flow

Metric FY2025
Cash from operations -$111.94M
Cash from investing -$170.96M
Cash from financing $275.34M
Net change in cash * -$7.56M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf